Trials / Completed
CompletedNCT03079544
Social Media-based Active Self-report on Incidence and Outcomes of Adverse Events in NK/TCL Patients
Social Media-based Patient Education and Active Self-report on Incidence and Outcomes of Adverse Events in Natural Killer/T-cell Lymphoma (NK/TCL) Patients
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 665 (actual)
- Sponsor
- Rong Tao · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to collect data from patients by social media and self-report on the adverse events and outcomes happened with patients with extranodal natural killer/T-cell lymphoma, nasal type, who are treated outside of clinical trials in China.
Detailed description
Extranodal natural killer/T-cell lymphoma, nasal type, is a rare subtype of non-Hodgkin lymphoma with relatively high incidence in China. L-asparaginase based chemotherapy are widely used with Chinese patients and has been reported to improve overall response and prolonged the long-term survival in some clinical trials with very limited patients. However, most patients were treated out of clinical trials in China. Therefore the real incidence of adverse events and treatment outcomes are largely unknown. This study is designed to evaluate the incidence of adverse events and treatment outcomes by social media-based (www.house086.com, www.wechat.com) self-report from patients who are treated out of clinical trials.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| COMBINATION_PRODUCT | L-Asparaginase or or Pegaspargase containing chemotherapy | Patients receive at least one cycle of combinational chemotherapy containing L-asparaginas or Pegaspargase. |
Timeline
- Start date
- 2017-03-08
- Primary completion
- 2021-08-30
- Completion
- 2021-08-30
- First posted
- 2017-03-14
- Last updated
- 2021-09-14
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT03079544. Inclusion in this directory is not an endorsement.